Willingness to Get the COVID-19 Vaccine among Residents of Slum Settlements

Slum residents are more vulnerable to COVID-19 infection. Without a specific treatment, vaccination became the main strategy against COVID-19. In this study, we determined the rate and factors associated with the willingness to get vaccinated against COVID-19 among slum residents and their main reasons associated with the vaccine intention. The study was conducted in Pau da Lima, a slum community in Salvador Brazil. In total, 985 residents were interviewed. Among them 66.0% (650/985) were willing to get vaccinated, 26.1% (257/985) were hesitant to take the vaccine and 7.9% (78/285) were not sure. The main reasons cited for vaccine hesitancy or being unsure were concerns about vaccine efficacy and potential side effects. In contrast, the main reasons cited for wanting the vaccine were the high incidence of COVID-19 cases and participants’ self-perception of their own health history. Multivariate analysis identified that COVID-19 vaccine hesitancy was associated with younger age and low social capital, summarized as low perceived importance of vaccination to protect one’s family, friends and community. Slum residents have been less willing to vaccinate than the general population. Social capital presents a critical opportunity in the design of communication campaigns to increase COVID-19 vaccine acceptance in slum settings.

Year of publication: 2021

Resource data

Content type:  Case study, Evaluation
Areas of work: Monitoring and evaluation, Social science
Region: Americas

Additional language downloads
No items found

More on Behaviours, Trust, Vaccine

Tool | 2021

This document provides answers for commonly asked questions about COVID-19 vaccines.

Strategy, Tool | 2021

This guidance is intended for those who are involved at the national and sub-national level in the design and delivery of demand and communication strategies on COVID-19 vaccination.

Case study | 2021

This study sought to identify transferable lessons for COVID-19 vaccination from the rollout of three vaccines that targeted adult groups in Africa and South America: MenAfriVac (meningitis A); 17D (yellow...